United Therapeutics CorporationUTHRNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank93
3Y CAGR-0.8%
5Y CAGR+6.6%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-0.8%/yr
vs +24.9%/yr prior
5Y CAGR
+6.6%/yr
Recent deceleration
Acceleration
-25.7pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.4x
Solid growth
Streak
2 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 6.29 | +24.4% |
| 2024 | 5.06 | +20.3% |
| 2023 | 4.20 | -34.8% |
| 2022 | 6.45 | +13.2% |
| 2021 | 5.70 | +24.9% |
| 2020 | 4.56 | +66.6% |
| 2019 | 2.74 | +3.3% |
| 2018 | 2.65 | -24.4% |
| 2017 | 3.51 | +6.7% |
| 2016 | 3.29 | - |